GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout ...
GENFIT va recevoir un paiement d’étape de 20 M$ suite au dépassement du seuil des 200 M$ de ventes nettes d’Iqirvo® par Ipsen dès sa première année complète de commercialisation Ventes nettes d’Iqirvo® dans la PBC par Ipsen atteignant 88 M$ au 4T25, portant le total annuel pour 2025 à 208 M$, déclenchant le premier paiement d’étape1 commercial pour GENFIT plus tôt que prévu Confirmation par Ipsen du lancement d’une Phase 3 dans la PSC, ouvrant une nouvelle opportunité de création de valeur potentielle pour GENFITL’étude de Phase 1b de GENFIT dans le CCA progresse comme prévu : Nouvelle coho...
Fastned's 4Q25 update shows faster station roll out but volume growth is still lagging BEV penetration. We make limited near term estimate changes, slightly lift longer term assumptions on higher BEV adoption, and increase capex forecasts. The new €200m loan facility is a positive, improving near term funding visibility, but we remain cautious given high leverage, funding needs beyond 2027, and softening charging volume growth. We maintain our HOLD rating and slightly raise our target price to €...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.